Similarly, the clinically approved Bruton Tyrosine Kinase (BTK) inhibitor, Ibrutinib, has been shown to exert potent anti-fibrotic and anti-tumour activities in mouse models of PDAC [93]. The gene discussed is BTK; the disease is neoplasm.